`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`thank the committee for the opportur..ity to add:-css
`
`you on this issue. My name is Bob Cloud, and I
`
`would like to briefly talk to you, first about my
`
`own long, personal use of Xyrem, ar.d I will call it
`
`Xyrem not GHB or sodium oxybate and, secondly, my
`
`very serious concerns as director of Narcolepsy
`
`Network, which is a national non-profit, primarily
`
`patient organization.
`
`In that capacity we have
`
`received funds, a minor amount of funds, perhaps
`
`ten percent of our revenues, from Orphan Medical
`
`over the last several years.
`
`First, my personal experience with Xyrem
`
`as a narcolepsy patient with cataplexy.
`
`I am 57
`
`years old, married, have two adult children, and I
`
`am an attorney in private practice, primarily
`
`family, probate and criminal law which sometimes
`
`17
`
`can be intense and have a few emotions attached to
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`it.
`
`T believe I am the first American to have
`
`used Xyrem for narcolepsy, and I am probably the
`
`longest continuing user of Xyrem which now
`
`approaches 19 years every night without fail. My
`
`narcolepsy/cataplexy symptoms began in the mid-30's
`
`and by age 39 included severe and recurring
`
`25
`
`cataplexy together with excessive daytime
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`sleepiness and sudden sleep attacks. My cataplexy
`
`caused r.umerous daily episodes of complete body
`
`collapse, such thut I couldn 1 t ]eave my office or
`
`home without ~isk of harm to myself or othc~s.
`
`Feeling any emotion, humor, anger or mere
`
`enthusiasm, would result in sudden immediate
`
`collapse.
`
`I guess we are all ignorant of what
`
`diseases feel like that we don 1 t have them, but my
`
`best description of the sudden collapse of
`
`cataplexy would be to imagine a puppet on strings
`
`and suddenly the strings, which are your muscle
`
`tone, arc immediately let go and so you fall to the
`
`13
`
`ground immediately, and your head comes down last
`
`14
`
`and whips against whatever -- sidewalk or table
`
`15
`
`corner or escalator or whatever might. be there.
`
`I
`
`16
`
`have been ·!"et;cued by police and emergency squads
`
`17
`
`and life guards and well-meaning strangers and
`
`18
`
`19
`
`20
`
`21
`
`friends.
`
`Obvio"J.sly no injury for me has been fatal
`
`because I am here, but unfortunately I do know
`
`others whof~e fall has occurred at the top of the
`
`22
`
`stairs and tiey fe:l down backwards and killed
`
`23
`
`24
`
`25
`
`themsel VE"!S, and there are others that I don't know
`
`about.
`
`In 1982 my treating physician sent me to
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`203
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`Sunnybrook Medical Center in 7oronto, Canada to
`
`begin presc:~ipt i ve use of Xyrem unde~- the ~escu:::-ch
`
`being conducted by Dr. Mortimer ~umelak. After
`
`three weeks I returned home and continued usi~g
`
`Xyrem, always prescribed by my local physician
`
`under his own individual investigational new drug
`
`application. My severe cataplexy symptoms
`
`disappeared almost overnight.
`
`I was immediately
`
`able to return to my full-time law practice and I
`
`have continued to this day to use Xyrem under that
`
`individual application and subsequently in the
`
`clinical trials under the Orphan Medical
`
`application. During these 19 years, I have never
`
`changed the dose.
`
`I have never experienced
`
`15
`
`tolerance.
`
`I have never noted side effects.
`
`16
`
`17
`
`18
`
`Simply stated, the drug is as safe and effective as
`
`it was on day one.
`
`It is hard to imagine a
`
`pharmaceutical product having such a quid:,
`
`19
`
`complete, safe and enduring benefit.
`
`20
`
`21
`
`22
`
`23
`
`2~
`
`25
`
`As director of Narcolepsy Network, I have
`
`said on a number of occasions that r think the
`
`greatest tragedy i.n the treatment of peop~e with
`
`narcolepsy is that Xyrem or GHB has not been
`
`available so that other patients couJd benefit from
`
`it as I have. Hopefully, this committee will
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`204
`
`1
`
`2
`
`3
`
`4
`
`remedy that.
`
`We are sensitive to the reports of
`
`injuries and deaths and other victimizations from
`
`the abuse of GHB and, as an organization, we work
`
`5 with law enforcement and community dr~19 agencies to
`
`6
`
`7
`
`partake in their activities to limit that and
`
`correct that.
`
`I think it is obvious that. Orphan
`
`8 Medical ls going above and beyond the cull of duty
`
`9
`
`to also contribute to restricting the unlawful use
`
`10
`
`of GHB.
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`In closing, I submit that our concern for
`
`patients with narcolepsy should receive your
`
`highest considerations so that people can
`
`rediscover their economic and particularly their
`
`family lives and avoid disability. Thank you.
`
`DR. KAWASo Thank you, Mr. Cloud. The
`
`next speaker is Cindy Pekarick from Pennsylvania.
`
`MS. PEKARICK: Hi. My name is Cindy
`
`Pekarick, and T am here today to tei.l you how GHB
`
`killed my daughter.
`
`In October of 199a, my
`
`daughter Nicole, a college student u.nd gym
`
`enthusiast met a new boyfriend who introduced her
`
`to a prorL1ct called Renewt.rient.
`
`In November she
`
`researched the product over the Internet and
`
`received on:y positive information. She could take
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`it before: bedtime and wake up in only four hours
`
`feeling refreshed, well-rest-=-d, ar:d a.21 her muscles
`
`would he completely recovered and ready for another
`
`wo~·kout.
`
`:n December I found out she was taking
`
`this supplement.
`
`I didn't believe the promises
`
`made by the advertisers. Arguments ensued and she
`
`promised she wouldn't drink it anymore. She was
`
`away at school from mid-January until April.
`
`In April she returned home. She was
`
`behind ir. all her bills. She was bJack and blue on
`
`12
`
`her arms and legs. She stopped attending classes,
`
`13
`
`and she kept losing things.
`
`In May T discovered
`
`14
`
`she had essentially dropped out of school.
`
`15
`
`16
`
`In June I could see mild c~anges in her
`
`behavior. She began taking power naps, as she
`
`17
`
`called them. She would sleep three hours in the
`
`18 middle of the day and get up at four o'clock and go
`
`19
`
`to work. She continued losing things and having
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`difficulty paying her bills.
`
`I searched her room
`
`and c:a~- but found no evidence of substu.nce abuse.
`
`By July, my younger daugl~te'!:", Noelle,
`
`inform~d me that Nicole was havir.g pt·oblems. She
`
`said, "mom, she isn't taking ar..ytf:inq bad o~-
`
`illegal. She takes a muscle supplem'=nt that
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`206
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`doesn 1 t agree with her. Sometimes she has bad
`
`reactions and she doesn 1 t even know it. She
`
`embarrasses herself and me when she acts weird and
`
`then goes to sleep. When she awakes she never
`
`remembers anything that she did. She started
`
`taking it once in a while so she could go to sleep
`
`right away after work when she got home. Then she
`
`started using it more often.
`
`It disgusts me to see
`
`her out of control. 11
`
`It was at this time I discovered Nicole
`
`had been taking GHB since November.
`
`I then began
`
`my own search over the Internet for more accurate
`
`information.
`
`In August, Nicole was found having a
`
`seizure in a public bathroom. She had urinated and
`
`defecated on herself while pulling at her clothes
`
`and hair and flailing her arms. She was rushed to
`
`the hospital where we arrived to find her
`
`unconscious, intubated, with her arms, legs and
`
`19 waist strapped to the bed. They claimed her
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`seizure was violent. She barely had a pulse when
`
`they found her.
`
`It was at this time I knew my daughter was
`
`addicted to whatever she was taking. There is
`
`absolut.ely no other reason why a young, bright,
`
`healthy woman would take a supplement that was
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`harmful.
`
`I begged the doctors to transfer her to a
`
`t~catment center for chemical dependency, but they
`
`said they wouldn't do it without the patient's
`
`permission. She was clueless as to why she was
`
`hospitalized and she had no recull of anything that
`
`happened to her. She was discharged.
`
`In September, Nicole, sweating profusely,
`
`8 with a red face and shaking hands while crying
`
`9
`
`said, "mom,
`
`I have to talk to you.
`
`I'm really
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`scared.
`
`I have a problem.
`
`I can't stop drinking
`
`it.'' T stood up, wrapped my arms around her and
`
`hugged ~er as hard as I could.
`
`I told her that she
`
`was on her way to getting better, that
`
`acknowledging that "g" had a hold on her was a step
`
`:in healing.
`
`On Monday morning, on her way to the
`
`treatment center, Nicole refused to go in. She
`
`cl a i.metj that "g" wasn't addictive; that she did the
`
`research and she was just having reactions to it.
`
`S~e said she was now in control of her life and
`
`futm··~. She stayed in counseling and, by the end
`
`of September, Nicole had applied, transferred, and
`
`was accepted at the university. She was excited.
`
`T~ings seemed okay on the surface but she was
`
`25
`
`hiding tremors, hallucinations und insomnia. She
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`~08
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`went days without sleeping but never told me.
`
`On October 3, 1999 at 2:00 p.m. she said
`
`she needed to take a nap before she went to work
`
`since she hadn't slept the nig~t before. She set
`
`the alarm for 4:00p.m. but she never heard it.
`
`She was in her final sleep. My firstborn child was
`
`found in bed, blue, at 6:00p.m. We found a bottle
`
`of GHB in the trunk of her car. The autopsy
`
`revealed she had GHB and GBL in her system at the
`
`10
`
`time of her death. No other chemicals were found.
`
`11
`
`12
`
`Nicole was an honor student, captain of
`
`two varsity teams and graduated third in her class.
`
`13
`
`For her undergraduate studies she majored in
`
`14
`
`15
`
`biology, with a plan to major in engineering for
`
`her master's degree. Her ultimate goal was to
`
`16
`
`become a biomedical engineer. She wanted to be
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`able to design body parts to ~elp extend people's
`
`lives. She understood that to function well, one
`
`had t.o be healthy. She was a loving, sensitive,
`
`caring and intelligent woman. Her only fault was
`
`thut she was naive. Thank you.
`
`DR. KAWAS: Thank you, Mrs. Pekarick.
`
`Tt:~
`
`~3
`
`next speaker is Eric Strain. Doctor Strain is from
`
`2·1
`
`25
`
`the College on Problems of Drug Dependence.
`
`DR. STRAIN: Thank you.
`
`I would like to
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`~09
`
`1
`
`thank the FDA and the members of the Peripheral and
`
`2 Central Nervous System Drug Adviso:!:"y Committee for
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`providing me the opportunity to speak. My name is
`
`Eric Strain.
`
`I am a professor in the Department of
`
`Psychiatry at Johns Hopkins University School of
`
`Medicine.
`
`I am a board-certified psychiatrist with
`
`qualifications in addiction
`
`psychiatry, and I am
`
`here today representing the
`
`College on Problems of
`
`D~·ug Dependence, CPDD.
`
`The College is the
`
`leading organization
`
`of
`
`drug abuse scientists in the
`
`United States.
`
`I am
`
`12
`
`also the former chairman of the FDA•s Drug Abuse
`
`13 Advisory Committee. T have sponsored my own travel
`
`14
`
`15
`
`16
`
`17
`
`to today•s meeting, and I have no relationship with
`
`Orphan or other pharmaceutical companies that make
`
`narcolepsy products.
`
`There are two point that I would like to
`
`18 make during these brief comments. The first is
`
`19
`
`that the College on Problems of Drug Dependence
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`would like to emphasize the importance of
`
`science-based assessments of new medications,
`
`especially as they relate to issues such as abuse
`
`liability evaluation and safety of abused products.
`
`The College wishes to stress the long history that
`
`has led to the establishment of reliab~e and valid
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`210
`
`1 methods for dete:!.-mining abuse potential. T::,.is work
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`includes both preclinical as well as clinical
`
`studies. Several academic medical centers contain
`
`rich experience in this area of research. Methods
`
`have been well tested, and outcomes from previous
`
`studies have helped inform and guide agencies such
`
`as the FDA in making determinations regarding abuse
`
`potential, therapeutic efficacy, and safety of new
`
`9 medications.
`
`10
`
`CPDD has played a key role in such
`
`11 matters, as its members are the primary group that
`
`12
`
`have conducted such studie~. The College wishes to
`
`13
`
`14
`
`strongly and forcefully advocate that decisions
`
`made by the FDA grow out of and be based upon
`
`15 well-conducted research, and whenever possible
`
`16
`
`decisions should be derived from well-controlled
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`studies and data driven.
`
`In order to achieve such
`
`goals, advice on substance o:J.buse related matters
`
`should be solicited from experts in the field.
`
`The second point T would like to make has
`
`to do with the Drug Abuse Adviso~y Committee. As
`
`the former, and the last c~airman of this advisory
`
`committee of the FDA,
`
`I be.~ ieve it is important for
`
`me to comment upon its termination. The Drug Abuse
`
`25 Advisory Committee has been dissolved by the FDA,
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`211
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`and in the process the FDA has lost an important
`
`resource that can inform d~cisions regarding
`
`substance abuse. To my knowledge, today's meeting
`
`is the first FDA advisory committee meeting since
`
`this termination where issues of drug abuse are an
`
`impo~tant element in your discussions.
`
`I am pleased to see that there are several
`
`drug abuse experts represented here today, however,
`
`I am concerned that the numbers do not allow the
`
`breadth of expertise that would have been found on
`
`the DAAC.
`
`Such breadth is essential to fully
`
`consider all of the issues involved in advising the
`
`FDA on the abuse potential of new medications, the
`
`extent of the public health consequences of such
`
`abuse, additional data that the FDA should require
`
`16
`
`companies provide, and recommendations regarding
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`post-marketing surveillance.
`
`The College is particularly concerned tr.at
`
`comparable experience and knowledge brought to the
`
`Drug Abuse Advisory Committee by expe~ts in the
`
`drug abuse field is no longer readily available to
`
`the FDA.
`
`In my experience as chairman of the
`
`committee, I was able to witness firsthand on
`
`repeated occasions the value of having a group of
`
`scientists and clinicians who could provide
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`212
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`informed knowledge and experience to the FDA on
`
`matte~s such as those that appear to be on today's
`
`agenda.
`
`The loss of the DACC to the FDA is
`
`significant and substantial, and adequate
`
`representation of dr.ug abuse issues on other
`
`advisory committees needs to be clearly
`
`demonstrated by the FDA.
`
`I speak on behalf of the
`
`9 College in expressing the College's continued
`
`10
`
`concern regarding the dissolving of this advisory
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`13
`
`19
`
`20
`
`21
`
`:::!2
`
`23
`
`24
`
`committee. Given the tragic consequences of drug
`
`abuse to our society, as exemplified by the
`
`previous speaker, its prevalence and the growing
`
`body of medications for the treatment of substance
`
`abuse disorders, it is particularly concerning that
`
`the FDA has decided to terminate this particular
`
`udvisory committee.
`
`Again, I wish to thank the FDA and this
`
`advisory committee for allowing me to make these
`
`comments today. The hope of the College is thut
`
`these companies will spur tangible demonstration of
`
`FDA's commitment to having adequate outside input
`
`by experts in the drug abuse field in the advisory
`
`committee process either through the renewal of the
`
`lS
`
`Drug Abuse Advisory Committee or through adequate
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`213
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`2J
`
`24
`
`2S
`
`and substantial representation by drug abuse
`
`experts on other advisory committees where issues
`
`of drug abuse may be of substantial importance.
`
`Thank you.
`
`DR. KAWAS: Thank you, Dr. Strain. The
`
`next speaker is Deborah Zvorsec. Dr. Zvorsec is
`
`from Hennepin County Medical Center in Minnesota.
`
`DR. ZVORSEC: Thank you very much. My
`
`research is in the area of gamma hydroxybutyratc
`
`abuse toxicity, addit.ion and withdrawal. Dr. Steve
`
`Smith and I, with others, published a case series
`
`in Morbidity and Mortality Weekly Report in
`
`February of '99 that described adverse events due
`
`to ingestion of dietary supplements containinq GRL,
`
`GHB precursor.
`
`I was the lead author of a case
`
`series of 1,4 butanediol toxicity that was
`
`published in The New England Journal of Medicine in
`
`January 2001. These toxicity episodes includ(~d two
`
`deaths that occurred with no co-intoxicants and no
`
`evidence of aspiration or asphyxiation or
`
`adulterants.
`
`I will focus today on GHB addiction.
`
`rn
`
`the course of our work, 0:!:'. Smith's and my name
`
`were listed or. the project GHB help site. We
`
`received calls from over 40 addicted patients from
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`714
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`25 states, and have treated an additional 5 cases
`
`of inpatient withdrawal at HCMC in f":inneapo!.is.
`
`The vast majority of these addicted people
`
`began using GHB to t~cat insomnia, anxiety,
`
`depression, chemical dependence or for
`
`body-building purposes, as recommended by
`
`7 marketers, websites and fringe pro-GHB physicians.
`
`8 Many, indeed, began with GHB, continued with GHB
`
`9
`
`and never used any of the dietary supplement
`
`10
`
`analogs. Our patients began with small doses,
`
`11
`
`12
`
`13
`
`14
`
`15
`
`often only at night, and discovered that it made
`
`them feel good; increased dosing frequency and, as
`
`tolerance developed, needed more GHB in order to
`
`feel good. Within months, they were taking GHB
`
`every one to three hours around the clock to avoid
`
`16 withdrawal symptoms. By the time they realized
`
`17
`
`18
`
`19
`
`;J:Q
`
`21
`
`22
`
`23
`
`that they might be physically dependent, attempts
`
`to abstain resulted in severe anxiety, insomn.ia,
`
`panic attacks and hallucinations.
`
`Their addiction destroyed their lives.
`
`They lost their spouses. They lost access to their
`
`children, their .iobs. They acquired tremendous
`
`debt to suppo~t their habit. They became comatose
`
`24 while driving and crashed their cars, frequently on
`
`25 multiple occasions. They called us in absolute
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`215
`
`1
`
`desperation. Their detox was freq~ently similar to
`
`the worst cases of delirium tremens, requlrin~I
`
`3
`
`large and often massive doses of sedatives, often
`
`4 with intubation.
`
`5
`
`Almost all patients suffered weeks or
`
`6 months of profound depression and anxiety uftcr
`
`7
`
`8
`
`deto:x:, and some also experienced muscle twltchi.r.g
`
`and tremors. Of the over 40 patients we have
`
`9 worked with, only a scant handful have remained
`
`10 GHB-free, frequently despite CD treatment. Many
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`have detox'd numerous times but continue to
`
`relapse, sometimes within hours of discharge from
`
`treatment. Unfortunately, many never lost fai.t.h i.n
`
`GHB and continued to be convinced that they could
`
`get back on it and use it responsibly. They
`
`continue to argue its health benefits.
`
`One of our patients was a 50-yea!· old
`
`businessman with his own business who began using
`
`GHB, not an analog, five years ago, initially for
`
`body-building purposes. Within months he had
`
`increased his dosir.q to around the clock. His life
`
`was entirely controll~d by the need to have GHB
`
`23 with him at all times. He tried numerous times to
`
`24
`
`25
`
`quit. His wife was unaware of his addiction. She
`
`described witnessing frequent frightening hypnotic
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`216
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`states, punctuated with clonic movements. She
`
`believed that his frequent states of apparent
`
`somnambulism were due to a sleep disorder but.
`
`despaired when a sleep specialist coi.lld not. cure
`
`him. This woman is a very bright professiocal who
`
`was totally unaware of GHB, as is the case with
`
`many family members.
`
`It was only on the mo~ning of
`
`his admission that she learned the truth. After
`
`six days of detox he was through the worse and
`
`appeared to be on the road to recovery.
`
`Psychiatrists treated him with sleeping merh"; and
`
`antidepressants, but within three days he was ~sing
`
`GHB again to control anxiety attacks and
`
`depression.
`
`GHB is perhaps the most addictive drug
`
`ever abused. Experienced drug users desc~ibc u
`
`euphoria that surpasses that of any othe'!'· d.Yug.
`
`18 Availability of off-label prescription presents
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`profound personal and public health risks. The
`
`fringe physicians who now promote GH3 will be
`
`joined by thousands of mainstream physir:ia.n::; with
`
`the approval of the FDA. The majority ot
`
`physicians are ignorant of the diverse health risks
`
`of GHB, as are toxicologists and law enfo:C"ement
`
`25
`
`officials. Users will seek Xyrem from p~ysicians
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`217
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`who don't recognize sodium oxybate as GHB und urc
`
`unfamiliar with the health risks. Patients will
`
`obtain prescriptions for sleep disorders, also for
`
`insomnia, depression, anxiety, t:::-eatment of alcohol
`
`and drug dependence and other conditions for which
`
`it has been touted.
`
`We know that addicts often use GHB and its
`
`analogs interchangeably. Their compound of choice
`
`is dependent on access, determined by cost,
`
`10
`
`perceived quality, ease of procurement. Clinical
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`literature reports one user who spent $200 per day.
`
`That comes to $70,000 per year. Our patients
`
`report ingestion of up to a bottle every one to two
`
`days, coming to $11,000 to $36,000 per year. A
`
`Xyrem prescription will be a bargain for such
`
`users, who will then avoid the high prices, erratfc
`
`availability and risks of supplement and solvent
`
`purchase. We know that many people a:::-e ufruid to
`
`19
`
`buy or make their own GHB due to risks of
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`contamination or errors of production. Xyrem, a
`
`pharmaceutical product of controlled quality.
`
`available by legal prescription, and with very
`
`little risk if found in their possession, will be
`
`very attractive. We know that users are watching
`
`fo~- the release of Xyrem. Recreational druq sites
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`218
`
`1
`
`2
`
`3
`
`post links to narcolepsy sites and publications
`
`about Xy~·em. One hotyellow98. com, for ~xample,
`
`instructs users "click here to find O'.Jt. when GHB
`
`4 will be released under the trade name of Xyrem."
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`DR. KAWAS: Your time is up, Dr. zvorsec.
`
`Please finish. Thank you very much, Dr. Zvorsec.
`
`Our nest speaker is Trinka Porrata of California.
`
`MS. PORRATA:
`
`I wish I had time to tell
`
`you the stories of 200 dead people that I know of,
`
`hundreds of t:ape victims and thousands of GHB
`
`overdoses, and About Caleb Shortridge, to whom our
`
`12 website www.projectghb.org is dedicated, about
`
`13 Matthew Coda and Joshua Parks to whom our GHB
`
`14
`
`15
`
`addiction hotl.ine is dedicated.
`
`I wis!l I could
`
`tell you about Ben Croman, Mike Fox, Tyler Johnson
`
`16
`
`and othe-r- young men from New Zealand to ~;·..:eden who
`
`17
`
`18
`
`either hav~ o~ are right now considering suicide
`
`because of th~ withdrawal from this drug; about
`
`19 more than 300 people I personally know about who
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`are horribly addicted to GHB, and who could each
`
`name at least one dozen people more just iike them.
`
`I have lived and breathed GH3 since June
`
`of 1996 when I was first assigned t.o hondlc it for
`
`the LAPD.
`
`Four young men collapsed. Two literally
`
`died and wer.e brought back to life by the
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`219
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`paramedics. One thing was clear, people were dying
`
`from GHB and it was being missed.
`
`It has been a
`
`heartbreaking five years, mixed with the privilege
`
`of learning more and teaching others to recogni::e
`
`the rape, overdose and deaths and getting rape
`
`victims into treatment and addicts help.
`
`It has
`
`been very lonely at times when the agencies who
`
`should care haven't.
`
`DEA has reviewed and documented 71 deaths
`
`10
`
`related to GHB but, basically, stopped counting
`
`11
`
`12
`
`13
`
`once the drug was controlled, for obvious reasons.
`
`No one at FDA has ever expressed interest in these
`
`cases. My database now includes over 200
`
`14 GHB-related deaths.
`
`In fact, Robert McCormick, of
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`the FDA's Orphan Drug Unit, told me emphatically he
`
`did not care how many people had died nor were
`
`addicted to it because he intended to approve it
`
`anyway. Something is wrong with this picture.
`
`This is the most horrid drug I have encountered in
`
`25 years as a police officer.
`
`Much new has come to light during the past
`
`two years, none of it good. Around the wo~·ld
`
`countries are just now awakening to their problems
`
`24 with GE3. Schedule IV by WHO is simply an
`
`25
`
`awakeni.ng to the problem. As we speak, countries
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`220
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`are restricting it. France is backing away.
`
`=:ngland is struggling with it. Sweden has an
`
`unrecognized addiction and suicide problem. New
`
`Zealand tri~d it as a prescription dr.ug and now
`
`reali7.es they screwed up royally. NIDA is
`
`currently releasing $2 million in research on this
`
`drug. This is not a time to be pushing it forward
`
`on an unsuspecting American citizenry.
`
`You are here today to approve GHB,
`
`disguised as sodium oxybate, for use with
`
`narcolapsy/cataplexy. Orphan's investors have been
`
`assured that you will do so. When the last meeting
`
`was cancelled the stock dropped 30 percent in
`
`frustration over it. You have not seen my
`
`videotapes of the day-to-day struggle of GHB
`
`addicts showing that GHB clearly gives previously
`
`healthy people symptoms that can only be described
`
`as temporary narcolepsy/cataplexy, just like the
`
`nine-year old you saw in the tape. Their heads
`
`ricochet off board room tables around this country.
`
`They bl"·eak mirrors. They are cut up. They crash
`
`cars. They die and kill others.
`
`It is destroying
`
`them. Their wives are terrified of their husbands
`
`and have no idea what is happening. They are
`
`25
`
`locked in psychiatric wards because doctors and
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`emergency rooms do not recognize GHB psychotic
`
`episodes.
`
`There are no answers for them. So, how
`
`can you approve this drug for use? My addicts
`
`suffer alone, much as narcoleptic/cataplectic
`
`patients do. Many do not have insurance or their
`
`insurance will not pay for this drug that is not
`
`recognized as an addictive drug.
`
`t am deeply concerned about the off-label
`
`use policy, enabling any doctor ultimately to
`
`prescribe it for any condition as I have no faith
`
`that its 11se will be limited to
`
`narcolepsy/cataplexy. Look at the chatter around
`
`14 Orphan about fibromylagia, a condition with vague
`
`15
`
`symptoms for which a drug seeker could easily get a
`
`16
`
`prescription.
`
`I know the vast majority of doctors
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`do not realize that sodium oxybatc, Xyrem, is GHB.
`
`I see no si.qnificant talk on the legitimate
`
`narcolepsy websites about it, but the message
`
`boards whe:re GHB addicts hand out a~-e buzzing.
`
`In
`
`fact, t.he key figures in illegal GHB Internet sales
`
`were post.ing on the website www.xyrem.com.
`
`There is very little drug diversion
`
`enforcemcr.t i.n the United States. Only a handful
`
`25
`
`of agencies devote any time to this.
`
`lt is a small
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`222
`
`1
`
`2
`
`po!.·tion of DEA effort. States are not prepared.
`
`They are not able to handle it. Therefore,
`
`3 Orphan's proposed voluntary ··- key word, voluntary
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`promises of distribution are friglltening.
`
`More importantly, the issue goes beyond
`
`diversion of Orphan's product to use of Orphan as a
`
`shield for possession of GHB in general.
`
`It would
`
`be unrecognized by law enforcement. Once in
`
`possession of that prescription and a bottle of
`
`Xyrem,
`
`the addict will be home free. There is no
`
`field test kit. All investigations of GHB are
`
`difficult. Encountering a prescription, real or
`
`counterfeit, and a bottle of Xyrem, real or
`
`counterfeit, the officer would have zero ability to
`
`identify it -- none; zero; nada.
`
`To those who claim real GHB is safe and
`
`only street stuff is dangerous, poppycock. My
`
`addicts have used everything from European
`
`pharmaceutical grade to bad stuff. The
`
`unprecedented split scheduling of GHB was unwise
`
`and unenforceable. We were forced to accept it.
`
`It was political, not science. The people in the
`
`cl:ini.cal trials have reason to obey; people in the
`
`streets do not.
`
`Tf I were to convey to you but one
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`223
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`thought, it would be that not enough information is
`
`known about GHB to approve it fer::· any purpose at
`
`this time, and certainly not appropriate for
`
`off-label use. Any approval at this point will
`
`tr:iqqer an absolute further epidemic of general
`
`abuse be-cause you will create an aura that it is
`
`safe.
`
`I ask you please table this issue until the
`
`NIDA research comes in. Please do not make this
`
`9 mist'ike.
`
`10
`
`DR. KAWAS: Thank you, Ms. Porrata. Our
`
`11
`
`next speaker is Matt Speakman from West Virginia.
`
`12 While Mr. Speakman is coming up,
`
`I just want to
`
`13
`
`remind everybody I am not trying to be mean;
`
`I am
`
`14
`
`not trying to be difficult, but we are trying to
`
`15
`
`keep the public hearing section of this meeting
`
`16
`
`do·,·m to under two hours and t.hat will only happen
`
`17
`
`18
`
`if everyone sticks to their five minutes. We would
`
`like: to let the committee get. a chance to have some
`
`19 more discussions for everyone. So, we greatly
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`appreciate honoring the time con.st~·aints. Mr.
`
`Speakm.::a.n?
`
`MR. SPEAKMAN' Thanks.
`
`I
`
`just wanted to
`
`say t.h,::'!r.ks. This is kind of a unique experience
`
`add::::·essinq doctors.
`
`It is really cool.
`
`My name is Matt Speakman ar.d I have
`
`AMN1003
`IPR of U.S. Patent No. 7,765,107
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`narcolepsy.
`
`I will describe very briefly my
`
`expertence.
`
`I have cataplexy also. My first
`
`experience was in chemistry class my junior year in
`
`high school. The professor pulled out the liquid
`
`nitrogen experiment and was freezing flowers and
`
`flicking them, making them shatter.
`
`I got very
`
`excited and he called us to the front of the room
`
`and, on my way up to the front of the room,
`
`I felt
`
`my legs start to buckle. This was the first time
`
`anything like this had happened.
`
`I had had trouble
`
`laughing a little bit because cataplexy sometimes
`
`has onset with laughter and emotion, but it wasn't
`
`very serious.
`
`I eventually just realized that I was
`
`going to fall. So, I went back to my desk and
`
`16
`
`collapsed on the desk with my face down in my arms,
`
`17
`
`18
`
`19
`
`kind of draped over the thing.
`
`It was humiliating.
`
`I couldn't move.
`
`I was awake and aware and I co'...lld
`
`still hear the class kind of looking around and
`
`20 what-not.
`
`21
`
`22
`
`23
`
`24
`
`25
`
`This started to happen more regularly and
`
`I started to fall asleep during class. My grades
`
`started slipping.
`
`I had to stop swimming.
`
`I was
`
`on t~e swim team. Falling asleep